Hall Ashley 4

What Happened
Ashley Hall, Chief Development Officer of Structure Therapeutics (GPCR), was granted a total of 106,779 equity awards on March 19, 2026: 47,706 ordinary shares reported as an acquisition at $0 and 59,073 shares reported as a derivative (RSUs) at $0. The filing records $0 paid — these are compensation awards, not open-market purchases or sales. The derivative entry refers to restricted stock units (RSUs), which are contingent rights to receive ordinary shares upon vesting.

Key Details

• Transaction date: 2026-03-19; filing date: 2026-03-23 (timely filed).
• Reported price/value: $0 for both entries (compensatory grant).
• Total awards: 47,706 shares + 59,073 RSUs = 106,779 share-equivalents.
• Shares owned after transaction: not disclosed in the Form 4 filing.
• Relevant footnotes from the filing:
  • F1: Ordinary shares may be represented by ADSs; 1 ADS = 3 ordinary shares.
  • F2: The 59,073 RSUs are contingent rights to ordinary shares; they vest 25% annually on each anniversary of March 1, 2026, subject to continued service.
  • F3/F4: Filing also includes notes about option pricing/vesting terms (exercise price tied to ADS trading price; option vesting schedule), though the reported transactions here are RSU/award grants.
• Filing timeliness: The Form 4 was filed within the required reporting window (reported transaction 3/19; filed 3/23).

Context: RSUs are derivative awards that convert to actual shares only as they vest; no shares were reported sold or purchased. Such grants are typically routine compensation for executives and do not, by themselves, indicate the insider’s market view. If awards are later settled as ADSs, remember each ADS equals three ordinary shares.